Reneo Pharmaceuticals, Inc. (RPHM) [Rocket]

In millions, except per share items	Dec-31-22	Dec-05-22	Dec-31-21	Dec-05-21	Dec-31-20	Dec-31-19
	10-K	8-K	10-K	8-K	10-K	S-1/A
Revenues	0.0	37.7	0.0	28.2	0.0	13.1
Revenue growth		33.9%			-100.0%
Cost of goods sold	0.0	53.8	0.0	39.8	0.0	15.5
Gross profit	0.0	-16.1	0.0	-11.6	0.0	-2.4
Gross margin		-42.8%		-41.4%		-18.1%
Selling, general and administrative [+]	16.1	16.1	11.6	11.6	3.6	2.4
General and administrative	16.1	16.1	11.6	11.6	3.6	2.4
Research and development	37.7		28.2		15.9
Other operating expenses		21.6		16.5		10.7
EBITDA [+]	-53.8	-53.8	-39.8	-39.8	-19.5	-15.4
EBITDA growth	35.2%	35.2%	103.8%		26.4%
EBITDA margin		-142.6%		-141.2%		-117.9%
Depreciation and amortization	0.1	0.1	0.1	0.1	0.0	0.0
EBIT [+]	-53.8	-53.8	-39.8	-39.8	-19.6	-15.5
EBIT growth	35.2%	35.2%	103.7%		26.4%
EBIT margin		-142.8%		-141.4%		-118.1%
Other income (expense), net [+]	1.9	1.9	0.0	0.0	0.1	3.0
Other non-operating income					0.1
Other	1.9	1.9	0.0	0.0	0.1	0.5
Pre-tax income	-52.0	-52.0	-39.8	-39.8	-19.5	-12.4
Income taxes	0.0	0.0	0.0	0.0	0.0	0.0
Tax rate	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Net income	-52.0	-52.0	-39.8	-39.8	-19.5	-12.4
Net margin		-137.8%		-141.2%		-95.0%

Basic EPS [+]	($2.12)	($2.12)	($2.19)	($2.19)	($9.60)	($6.38)
Growth	-3.2%	-3.2%	-77.2%		50.3%
Diluted EPS [+]	($2.12)	($2.12)	($2.19)	($2.19)	($9.60)	($6.38)
Growth	-3.2%	-3.2%	-77.2%		50.3%

Shares outstanding (basic) [+]	24.5	24.5	18.1	18.1	2.0	1.9
Growth	35.0%	35.0%	794.6%		4.1%
Shares outstanding (diluted) [+]	24.5	24.5	18.1	18.1	2.0	1.9
Growth	35.0%	35.0%	794.6%		4.1%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.